Ammori John B, Pelletier Shawn J, Mathur Amit, Cohn Joshua, Ads Yasser, Campbell Darrell A, Magee John C, Englesbe Michael J
Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
Pediatr Transplant. 2008 Mar;12(2):174-9. doi: 10.1111/j.1399-3046.2007.00783.x.
Surgical complications following pediatric liver transplantation are common and expensive. We examined the incremental costs of surgical complications and determined who pays for these complications (center or payer). We reviewed the records of 36 pediatric liver transplant patients aged <or=12 yr transplanted between July 1, 2002 and December 31, 2005. The association of recipient and financial data points was assessed. On univariate analysis, total hospital costs were significantly increased in patients with ACR, PNF, HAT, biliary complications, and ARF. Reimbursement by the payer was significantly increased in patients with PNF, HAT, biliary complications, and ARF. Hospital profits were significantly decreased in recipients with ACR and pneumonia. Multiple linear regression models (controlling for recipient factors) revealed that ARF and HAT were independently associated with a significant increase in median hospital costs (incremental costs of $238,990 and $125,650, respectively). ARF and HAT were also independently associated with a significant increase in median reimbursements (incremental costs of $231,611 and $125,287, respectively). No complications were independently associated with hospital margins. All parties (patient and families, physician, payer, and medical center) should benefit from quality improvement efforts, with payers having the largest financial interest.
小儿肝移植术后的手术并发症很常见且费用高昂。我们研究了手术并发症的额外费用,并确定了这些并发症的费用由谁承担(中心或付款方)。我们回顾了2002年7月1日至2005年12月31日期间接受肝移植的36例年龄≤12岁的小儿患者的记录。评估了受者和财务数据点之间的关联。单因素分析显示,发生急性细胞排斥反应(ACR)、原发性无功能(PNF)、肝动脉血栓形成(HAT)、胆道并发症和急性肾衰竭(ARF)的患者,总住院费用显著增加。发生PNF、HAT、胆道并发症和ARF的患者,付款方的报销费用显著增加。发生ACR和肺炎的受者,医院利润显著下降。多元线性回归模型(控制受者因素)显示,ARF和HAT分别独立与住院费用中位数显著增加相关(额外费用分别为238,990美元和125,650美元)。ARF和HAT还分别独立与报销费用中位数显著增加相关(额外费用分别为231,611美元和125,287美元)。没有并发症与医院利润独立相关。所有各方(患者及其家属、医生、付款方和医疗中心)都应从质量改进措施中受益,其中付款方的经济利益最大。